The FDA just made Ozempic even more expensive — here’s how
"Novo Nordisk relies heavily on the American market, with more than half of its sales coming from the United States. This dominance helped sustain Denmark’s economy, preventing a recession.
The company's dependence on U.S. consumers is reflected in its steep pricing. Ozempic costs $900 per month, while Wegovy is priced at $1,300 — a prohibitive expense for many Americans. For a time, an affordable alternative existed. When the federal government declared a semaglutide shortage, compounding pharmacies were allowed to produce lower-cost versions, offering them for hundreds of dollars less than the brand-name drugs.
That changed in February. Holdovers from the Biden administration declared the shortage over and set a deadline for compounding pharmacies to stop selling semaglutide alternatives. This move effectively drove the drug’s cost from under $200 back to more than $1,000..."
|